BlackRock Inc. reduced its position in shares of Balchem Co. (NASDAQ:BCPC) by 1.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,873,787 shares of the basic materials company’s stock after selling 84,205 shares during the quarter. BlackRock Inc. owned about 15.07% of Balchem worth $475,829,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norway Savings Bank bought a new position in shares of Balchem during the 3rd quarter valued at approximately $27,000. Harbor Investment Advisory LLC boosted its position in shares of Balchem by 104.7% during the 3rd quarter. Harbor Investment Advisory LLC now owns 348 shares of the basic materials company’s stock valued at $34,000 after acquiring an additional 178 shares during the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Balchem by 11.3% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,561 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 159 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Balchem during the 3rd quarter valued at approximately $216,000. Finally, Stephens Inc. AR boosted its position in shares of Balchem by 175.4% during the 2nd quarter. Stephens Inc. AR now owns 2,264 shares of the basic materials company’s stock valued at $215,000 after acquiring an additional 1,442 shares during the last quarter. Hedge funds and other institutional investors own 77.89% of the company’s stock.
Shares of BCPC opened at $103.81 on Friday. The company has a market cap of $3.36 billion, a PE ratio of 40.71 and a beta of 0.57. The business has a fifty day moving average of $102.65 and a 200 day moving average of $97.57. Balchem Co. has a 52-week low of $78.30 and a 52-week high of $113.93. The company has a quick ratio of 2.82, a current ratio of 3.95 and a debt-to-equity ratio of 0.25.
A number of analysts recently issued reports on BCPC shares. Zacks Investment Research upgraded Balchem from a “hold” rating to a “buy” rating and set a $114.00 price target for the company in a research report on Tuesday, November 10th. HC Wainwright raised their price target on Balchem from $104.00 to $126.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, BidaskClub downgraded Balchem from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $113.33.
In other Balchem news, VP Scott C. Mason sold 3,000 shares of the business’s stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $103.00, for a total value of $309,000.00. Following the completion of the sale, the vice president now directly owns 9,675 shares of the company’s stock, valued at approximately $996,525. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.38% of the company’s stock.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
See Also: Understanding the two types of arbitrage
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.